1. Home
  2. BDSX vs DBVT Comparison

BDSX vs DBVT Comparison

Compare BDSX & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BDSX
  • DBVT
  • Stock Information
  • Founded
  • BDSX 2005
  • DBVT 2002
  • Country
  • BDSX United States
  • DBVT France
  • Employees
  • BDSX N/A
  • DBVT N/A
  • Industry
  • BDSX Precision Instruments
  • DBVT Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • BDSX Health Care
  • DBVT Health Care
  • Exchange
  • BDSX Nasdaq
  • DBVT Nasdaq
  • Market Cap
  • BDSX 115.4M
  • DBVT 102.0M
  • IPO Year
  • BDSX 2020
  • DBVT N/A
  • Fundamental
  • Price
  • BDSX $0.61
  • DBVT $6.46
  • Analyst Decision
  • BDSX Strong Buy
  • DBVT Strong Buy
  • Analyst Count
  • BDSX 3
  • DBVT 2
  • Target Price
  • BDSX $2.93
  • DBVT $22.50
  • AVG Volume (30 Days)
  • BDSX 276.1K
  • DBVT 1.1M
  • Earning Date
  • BDSX 05-07-2025
  • DBVT 05-06-2025
  • Dividend Yield
  • BDSX N/A
  • DBVT N/A
  • EPS Growth
  • BDSX N/A
  • DBVT N/A
  • EPS
  • BDSX N/A
  • DBVT N/A
  • Revenue
  • BDSX $71,323,000.00
  • DBVT $4,200,000.00
  • Revenue This Year
  • BDSX $32.90
  • DBVT $1,679.52
  • Revenue Next Year
  • BDSX $24.65
  • DBVT $535.67
  • P/E Ratio
  • BDSX N/A
  • DBVT N/A
  • Revenue Growth
  • BDSX 45.30
  • DBVT N/A
  • 52 Week Low
  • BDSX $0.59
  • DBVT $0.44
  • 52 Week High
  • BDSX $2.04
  • DBVT $7.28
  • Technical
  • Relative Strength Index (RSI)
  • BDSX 33.15
  • DBVT 65.77
  • Support Level
  • BDSX $0.63
  • DBVT $3.91
  • Resistance Level
  • BDSX $0.78
  • DBVT $7.28
  • Average True Range (ATR)
  • BDSX 0.07
  • DBVT 0.60
  • MACD
  • BDSX -0.01
  • DBVT 0.20
  • Stochastic Oscillator
  • BDSX 9.13
  • DBVT 75.67

About BDSX Biodesix Inc.

Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.

About DBVT DBV Technologies S.A.

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Viaskin targets specific antigen-presenting immune cells in the skin, called Langerhans cells, that capture the antigen and migrate to the lymph node to activate the immune system without passage of the antigen into the bloodstream, minimizing systemic exposure in the body. Its main product candidate is Viaskin Peanut for the treatment of peanut-allergic patients.

Share on Social Networks: